Abstract 351P
Background
Aortic stenosis is the most common valvular complication of mediastinal radiotherapy. In 2016 was shown that not only radiotherapy but chemotherapy with anthracyclines alone may provoke the development of valvular heart diseases (VHD). But there are still not clear time frames of VHD development.
Methods
We present a single-center retrospective analysis of a cohort with breast cancer history who were treated in cardiology departments. Total 91 patients were included in this study. ECHO data and time till first symptoms and surgical treatment were assessed in all patients.
Results
Different VHD were revealed in 48.35% (n=44) of patients. Among them 54.5% (n=24) had aortic stenosis, 34.1% (n=15) – mitral regurgitation, 4.5% (n=2) – mitral stenosis with regurgitation, 2.3% (n=1) – isolated aortic regurgitation and the same number of isolated mitral stenosis. During 15 months 25 patients were undergoing surgical treatment. In 2 of them VHD was first diagnosed before cancer treatment, so they weren’t included in the subsequent analysis. The oncological age in operated patients was 60 [42; 68] years. The time till first signs of VHD was 8 [4; 16.5] years. In all patients dyspnea was presented, 39% of patients had angina and only in 21.7% had presyncopes and syncopes. The median time from oncological age till surgery was 11 [7; 22] years. We also revealed correlation between oncological age and time till first VHD signs and surgical treatment (r = -0.76 and r = -0.71 respectively).
Conclusions
Given the widespread prevalence of degenerative aortic stenosis in older age patients, it is advisable to assess valves condition not only before radiation and chemotherapy but also recommend more frequent echocardiographic monitoring after, as well as use of new visualization techniques, such as CT (calcium score) and 18F-NaF PET-CT (as marker of calcification).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session